Geovax Labs, Inc. · NASDAQ:GOVX
Geovax Labs — Q3 2021 Earnings Presentation
24 slides from Geovax Labs's earnings presentation, Nov 12, 2021
Slide 1: Corporate Update Conference Call
os s e Update ~~ Conference Call = November 11, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements © Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private ® Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circums
Slide 3: GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update
<Gevvax> Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs GeoVax Reports 2021 Third Quarter Financial Results and Provides Corporate Update ATLANTA, GA, November 11,2021 ~ GeoVax Labs, Inc. (Nasdaq: GOV), a biotechnology company developing immunotherapies ad vaccines ‘agains
Slide 4: Accelerating Clinical Development
Accelerating Clinical Development =
Slide 5: Addressing Deadly Challenges Worldwide
Addressing Deadly Challenges Worldwide © wheel Babe ay
Slide 6: GeoVax and City of Hope Agreement for COVID-19 Vaccine
G BBS Cityof Hope. * — GeoVax and City of Hope Aunounce Agreement to Accelerate Development aud Commercialization for City of Hope's COVID-19 Vaccine Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients Complements GeoVas’s Pan-Coronavirus Vaccine Program ATLANTA, GA and DUART
Slide 7: Transaction Provides Exclusive IP Rights to an Advanced Covid-19 Vaccine
Transaction Provides Exclusive IP Rights to an Advanced Covid-19 Vaccine in Phase 2 Clinical Testing Licensing of COHO4S1 immediately strengthens our presence in SARS- CoV-2 prevention market Currently evaluating the safety and immunogenicity of the multi- antigen COH04S1 vaccine to a single antigen
Slide 8: Clinical Development of COH04S1
Cityof Hope. CLINICAL DEVELOPMENT OF COH04S1 A synthetic multiantigen modified-vaccinia Ankara-based COVID-19 vaccine expressing SARS-CoV-2 Spike and Nucleocapsid antigens NOVEMBER 11, 2021 Flavia Chiuppesi, Ph.0., Felix Wussow, Ph.D. and Don J. Diamond, Ph.D. Department of Hematology & Hematopoieti
Slide 9: Synthetic MVA (sMVA) as a vaccine platform for COH04S1
Synthetic MVA (sMVA) as a vaccine platform for COH04S1 a @ Nantigen A S antigen + sy . coll * Spike (S) full-length, Wuhan strain: ae ©) ee co Main target of neutralizing antibodies © Co-dominant target of cellular immunity v a] Helper vius) = Nucleocapsid (N), Wuhan strain: = <? Z co Co-dominant ta
Slide 10: Summary of COH04S1 Preclinical Studies
Summary of COH04S1 Preclinical Studies a + SMVA platform and COHO4S1 immunogenicity in mice published in 2020 + COHO4S1 showed protective efficacy in animal models: hamsters and non-human primates (NHP) * COHO4S1 conferred protection against SARS-CoV-2 via parenteral and mucosal vaccination + Immuno
Slide 11: COH04S1 Phase 1 Clinical Trial in Healthy Adults
COH04S1 Phase 1 Clinical Trial in Healthy Adults a ClnicalTrials.Gov NCT04639466 (12/10/2020 started, 06/02/21 closed for accrual) Trial design: 3 dose levels (DL1-3) with 4-6 open-label sentinels at each DL followed by 35 randomized against placebo DL1=1x10pfuldose, same low dose as used in mice DL
Slide 12: Binding Antibodies to S, RBD, N in Healthy Adults Immunized with COH04S1
Binding Antibodies to S, RBD, N in Healthy Adults Immunized with COH04S1 at different dose levels (DL) Spike la Receptor Binding Domi (RBD) IgG ey © OU sats a O12 ser oe DL ern © Oli serine OL2sernds DL senna Binding antibody endpointtters induced by COHO4S1 in sentinel subjects vaccinated with DL1,
Slide 13: Neutralizing Antibodies Against Wuhan, Alpha, Beta, and Gamma VOC
Neutralizing Antibodies Against Wuhan (D614G), Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1) VOC by Pseudovirus Assay Neutralizing titers DL1 Neutralizing titers DL2 “> D61G Alpha © 05146 Aba Bola © anna + Bota Gonma Neutralizing titers DL3 DOHG Apa © Bot Garena 3 Log. NT50 Log. NTO ‘Neutralizing
Slide 14: T-Cell Responses to S and N antigens
T-Cell Responses to S and N antigens (IFNy and IL-4 secretion) ry Thi Tha WL Spike WL Nucleocapsia ‘ ey Dey Atall DL.COHO4S1 predominantly induced robust T cell responses of the Th’-type (IFNy) rather than Th2-type (IL-4) WCitya Hope
Slide 15: Phase 2 Trial — Immunocompromised Patients
Phase 2 Trial— Immunocompromised Patients Diminished antibody responses compared to healthy vaccinated individuals have been shown in immunocompromised patients provided mRNA COVID-19 vaccines ACOVID-19 vaccine which favors broader induction of cellular immune responses may confer improved protectiv
Slide 16: Phase 2 Trials — Booster vaccination
Phase 2 Trials — Booster vaccination a = Governments have started recommending 3rd doses of currently authorized COVID-19 vaccines * Inthe US high risk subjects are eligible for a booster if they received Pfizer/Modena vaccines. All individuals who have received J&J vaccine are eligible for a booste
Slide 17: GeoVax — COH04S1: Synergies
GeoVax — COH04S1: Synergies = * The use of MVA as a vaccine vector is the core technology of GeoVax * Experimental products for use against a diverse set of infectious diseases in different stages of preclinical and clinical development * Funding partnerships with multiple US government agencies * C
Slide 18: Financial Update
Financial Update
Slide 19: Consolidated Balance Sheet Information
GeoVax Labs, Inc. Consolidated Balance Sheet Information (amounts in thousands, except share information) Sep 30, Dec 31, 2021 2020 Assets Cash and cash equivalents $ 18,107 $ 9,884 Other current assets 53 351 Total current assets 18,160 10,235 Property and other assets, net 180 Total assets Liabili
Slide 20: Consolidated Statements of Operations Information
GeoVax Labs, Inc. Consolidated Statements of Operations Information (amounts in thousands, except share and per share information) Three Months Ended Sep 30, Nine Months Ended Sep 30, 2021 2020 2021 2020 Grant and collaboration revenue $ 30 $ 4150S 221 $ 1,572 Operating expenses Research and develop
Slide 21: GeoVax Immuno-Oncology Portfolio
GeoVax Immuno-Oncology Portfolio 2020 vs. 2021 MUC1 Solid tumors 1. MVA-VLP based, experimental 2. Preciinical 3. Internal funding HPV focused MVA-based Precinical {ntemel funding Head & Neck Cancer 2 =) — ‘MUC1 Solid tumors Cinical candidete seloctod GMP manufacturing intiated Research and clinical
Slide 22: GeoVax Infectious Diseases Portfolio
GeoVax Infectious Diseases Portfolio 2020 vs. 2021 SARS CoV-2 Universal “Pan” Coronavirus 1, MVAMLP based 2. Design and construction 3. Internat funding SARS CoV-2COH04S1 1. AGiy of Hope concept for ‘unique product 22 =) ed SARS CoV-2Universal “Pan” Coronavirus 1. Lead candidate identified - GEO-cmo
Slide 23: f ACh Se Sion. Gato
3 f ACh Se Sion. Gato ‘ - CGdoVvax>
Slide 24: Thank You
Thank You Creating Vaccines to Serve Humanity CGedVvax> Vaccines Serving Humanity (Geovar tas, ne Investr@geovaccom re-see-7220, 1800 axe Parone, Sute 380, ‘Manta, GA 30060, Fa (678) 264-7281 ven geovarcon NASDAQ: GOVX